Table 1.
Summarized data associated with PD-1/PD-L1/sPD-L1 expression in DLBCL
| Study (References) |
No. | Methodology (Used Antibody) |
Cut-Off Value | Frequency | Clinical & Prognostic Comments |
|---|---|---|---|---|---|
| Data associated with PD-1 expression | |||||
| Ahearne M.J. [49] | 70 | ND | ≥ median value | PD-1+ cells, 50% | PD-1+ cells were associated with better OS. The cell numbers positively correlated with numbers of CD4+ cells. |
| Kiyasu J. [43] | 236 | NAT105 (Abcam) | ≥ median value | PD-1+ cells, 50% | PD-1+ TILs were lower in patients with B symptoms, EN sites, bulky mass, non-GC type and PD-L1+ DLBCL. |
| Kwon D. [50] | 126 | MRQ-22 (Cell Marque) |
≥ 1 PD-1+ cell | PD-1+ cells, 68.6% | PD-1+ TILs were associated with better PFS and OS. Number of the TILs positively correlated with PD-L1+ and mPD-L1+. |
| Fang X. [51] | 76 | MRQ-22 (ZSGB-BIO) |
PD-1 expression | PD-1+ cells, 39.5% | PD-1+ TILs were associated with better OS. |
| Muenst S. [52] | 184 | Polyclonal Ab. (AF1086) | > 168/mm2 or 2.8% | ND | PD-1+ TILs were not significantly associated with survivals. |
| Cohen M. [53] | 102 | (AbD Serotec) | PD-1+ cell ≥ 13.1% | PD-1+ cells, 50% | High PD-1 cell numbers were associated with poor EFS. |
| Data associated with PD-L1 expression | |||||
| Siddiqi N. [54] | 52 | (Abcam EPR1161, 28-8 & SP263) | ND | ND | Higher PD-L1 expression in tumor cells correlated with more aggressive disease |
| Xing W. [55] | 86 | (E1L3N) | PD-L1+ ≥ 30% | PD-L1+ TC, 16% mPD-L1+ MEC, 27% |
PD-L1+ tumor cells correlated with poor survivals. |
| Fang X. [51] | 76 | (SP142, ZSGB-BIO) | PD-L1+ ≥ 10% | PD-L1+ TC, 26.3% mPD-L1+ MEC, 27% |
PD-L1+ tumor cells correlated with worse outcome in univariate analysis, but not multivariate analysis. |
| Hu L.Y. [56] | 204 | (Cell Signal tech) | PD-L1+ ≥ 10% | PD-L1+ TC, 49.0% mPD-L1+ MEC, 21.6% |
PD-L1+ in tumor cells was an independent risk factor with poor OS. |
| Dong L. [57] | 100 | Polyclonal Ab (Abcam ab153991) |
PD-L1+ ≥ 5% | PD-L1+ TC, 54.0% | PD-L1+ tumor cells were associated with poor outcomes. |
| Kiyasu J. [43] | 1253 | Monoclonal Ab (EPR1161) |
PD-L1+ ≥ 30% mPD-L1+ ≥ 20% |
PD-L1+ TC, 10.5% mPD-L1+ MEC, 15.3% |
PD-L1+ was significantly associated with B symptoms, high IPI risk group and non-GC type. PD-L1+ PAX5+ tumor cells correlated with inferior OS. |
| Data associated with sPD-L1 level | |||||
| Rossille D. [58] | 288 | PDCD1LG1 ELISA | Cut-off value, 1.52 ng/mL | Elevated, 50.7% | Elevated sPD-L1 was associated with poor prognosis. |
| Rossille D. [59] | 225 | PDCD1LG1 ELISA | Cut-off, median value | Elevated, 50% | High sPD-L1 was an adverse prognostic factor. |
| Fest T. [60] | 288 | PDCD1LG1 ELISA | Cut-off, 95th percentile | ND | High sPD-L1 was associated with inferior OS in DLBCL patients treated immuno-chemotherapy. |
| Keane C. [61] | 158 | PDCD1LG1 ELISA | ND | ND | sPD-L1 was not significantly associated with prognosis. |
sPD-L1, soluble PD-L1; Ab, antibody; TIL, tumor infiltrating lymphocyte; EN, extranodal; TC, tumor cell; MEC, microenvironment cell; PFS, progression-free survival; OS, overall survival; ND, not described; EFS, event-free survival; IPI, international prognostic index; GC, germinal center; mPD-L1; microenvironmental PD-L1.